We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Method Identifies Fat Malabsorption

By LabMedica International staff writers
Posted on 10 Sep 2014
Print article
Agilent Technologies\' Series 1200 high pressure liquid chromatography (HPLC) system
The Series 1200 high pressure liquid chromatography (HPLC) system (Photo courtesy of AGILENT)
A novel clinical test known as the Serum Retinyl Palmitate Test (RP) has been assessed and validated for the diagnosis of fat malabsorption, and compared to the fecal fat test (FFT).

The differential diagnosis for malabsorptive diarrhea is broad, encompassing luminal, mucosal and lymphatic disorders involving different organ systems and the possibility of undiagnosed systemic endocrine or immunodeficient diseases also highlights the importance of a thorough work-up.

Clinical biochemists at the University of Calgary (AB, Canada) carried out a case-control study on patients identified with chronic diarrhea, defined as persistent symptoms for greater than four weeks, and suspected malabsorption. Healthy control subjects were also recruited. Blood samples were collected at intervals after the administration of oil-soluble vitamin A. A fecal fat test was conducted on samples of patients after the consumption of 100 grams of a fat diet. Patients were defined as malabsorbers if the 72-hour stool fat excretion was greater than 5.9 g/day.

Serum levels of retinol (vitamin A) and RP were measured by reversed-phase high pressure liquid chromatography (HPLC; Waters; Milford, MA, USA). The detection limit for retinol was 0.18 mg/L and for retinyl-palmitate, it was 0.02 mg/L. Sixteen patients completed this study, 8 cases and 8 control subjects. Fecal fat results were available for 15/16 patients. The sensitivity of the FFT was 100%, but the FFT specificity was 42%, as 4/7 control patients were identified as malabsorbers. Cases with short bowel syndrome (SBS) had the lowest RP levels, but this did not meet statistical significance. There was no significant difference for serum RP levels when comparing cases and control patients.

The authors concluded that the RP test did identify patients with severe malabsorption secondary to SBS, but the performance of the RP test in patients with malabsorption from non-SBS etiologies was poor. However, the so-called gold standard, 72-hour FFT, had poor performance characteristics, highlighting the need for more useful diagnostics in identifying malabsorption. The study was published on August 8, 2014, in the journal Clinica Chimica Acta.

Related Links:

University of Calgary 
Waters 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more